Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.39 |
| ▸ | TK2 | O00142 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342615 | 0.89 | TK1 (0.39) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL7025013 | 0.88 | TK1 (0.38) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL6753364 | 0.87 | TK1 (0.41) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL13387567 | 0.85 | TK1 (0.44) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL8053437 | 0.83 | TK1 (0.42) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL28182722 | 0.83 | TK2 (0.46) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL2877649 | 0.82 | TK1 (0.43) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL28190357 | 0.82 | TK2 (0.47) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL27878939 | 0.81 | TYMP (0.46) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL7453796 | 0.80 | TK1 (0.40) | TK1ALDH1A1ALBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759318-B1 | Identification of novel pathways, genes and promoter motifs regulating adipogenesis | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7227014-B2 | Antisense modulation of apolipoprotein (a) expression | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1648910-A2 | ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1633302-A2 | MODULATION OF APOLIPOPROTEIN (A) EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2006026485-A2 | MODULATION OF HIF1-BETA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1629084-A2 | MODULATION OF C-REACTIVE PROTEIN EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| EP-1623046-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1597366-A1 | MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION | Antisense Therapeutics Ltd (AU) | 2005-11-23 | — | — | EP | disclosed |
| EP-1578927-A2 | ANTISENSE MODULATION OF NAV1.3 EXPRESSION | Pharmacia Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1567538-A2 | ANTISENSE MODULATION OF GFAT EXPRESSION | Pharmacia Corporation (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2000050439-A1 | ANTISENSE MODULATION OF Smad4 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000050437-A1 | ANTISENSE MODULATION OF Smad2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| US-6100090-A | COMPOUND 8 TO 30 NUCLEOBASES IN LENGTH TARGETED CODING REGION OF HUMAN PHOSPHATIDYL INOSITOL 3'-KINASE P85; THERAPY AND DIAGNOSIS OF DISEASES RELATED HORMONE AND GROWTH FACTOR RECEPTORS AND ONCOGENE PRODUCTS | ISIS PHARMACEUTICALS INC. (US) | 2000-08-08 | — | — | US | disclosed |
| WO-2000040595-A1 | ANTISENSE MODULATION OF NOVEL ANTI-APOPTOTIC BCL-2-RELATED PROTEINS | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000036150-A1 | ANTISENSE MODULATION OF ELK-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000034303-A1 | METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034302-A1 | ANTISENSE MODULATION OF EGR-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000032817-A1 | ANTISENSE MODULATION OF G-ALPHA-16 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000031103-A1 | ANTISENSE MODULATION OF MEK2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031111-A1 | ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |